Pharmaceutical intermediates
Momelotinib Dihydrochloride Monohydrate Intermediates
2 pharmaceutical intermediates for Momelotinib Dihydrochloride Monohydrate. Indication: Myelofibrosis.
About Momelotinib Dihydrochloride Monohydrate
- Originator
- Glaxosmithkline Llc; Gilead Sciences Inc
- Indication
- Myelofibrosis
- Approved Date
- 09/15/2023
- NCE Patent
- 09/15/2028
- DS/DP
- 01/03/2030
Available intermediates
2 intermediates currently listed for Momelotinib Dihydrochloride Monohydrate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 4-(2-(4-MorpholinophenylaMino)pyriMidin-4-yl)benzoic acid | 945749-71-3 | / | / |
| 4-Morpholinophenylguanidine | 247234-41-9 | / | / |
Building toward Momelotinib Dihydrochloride Monohydrate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →